An analyst said the news could negatively affect shares of a successor to the company that developed rapastinel - which Allergan bought in 2015 - given that its drugs belong to the same class.
The drug, a reformulation of ketamine, was approved for patients who have failed on other antidepressants. The original form of ketamine, approved as an anesthetic, has long been explored as a treatment for depression.
In a recent interview, Esperion president and CEO, Sheldon Koenig talks about the reality of statin intolerance and his company’s expansion into new diseases
The company's shares were down more than 4 percent in Monday morning trading after the agency's decision, which itself followed a negative AdCom vote in November.
Northwestern University biotech spinout Naurex just raised $80 million for its CNS drug that targets major depressive disorder – a real win for the psychiatric med space, which has few significant contenders at present. The money’s meant to further develop GLYX-13, an NMDA receptor modulator that’s on the cusp of entering Phase III trials to treat major […]